SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut

Sarepta Therapeutics, Inc. (SRPT) reported first-quarter 2025 adjusted loss of $3.42 per share against the Zacks Consensus Estimate for earnings per share (EPS) of 35 cents. This miss was largely due to a one-time charge incurred by the company to close the recently signed multi-billion-dollar deal with Arrowhead Pharmaceuticals . In the year-ago period, the company posted an adjusted EPS of 72 cents.The adjusted figures exclude depreciation and amortization costs and stock-based compensation expenses. Incl ...